DE3825667C2 - - Google Patents

Info

Publication number
DE3825667C2
DE3825667C2 DE3825667A DE3825667A DE3825667C2 DE 3825667 C2 DE3825667 C2 DE 3825667C2 DE 3825667 A DE3825667 A DE 3825667A DE 3825667 A DE3825667 A DE 3825667A DE 3825667 C2 DE3825667 C2 DE 3825667C2
Authority
DE
Germany
Prior art keywords
imexon
proliferation
cell
induced
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3825667A
Other languages
German (de)
English (en)
Other versions
DE3825667A1 (de
Inventor
Uwe Prof. 6140 Bensheim De Bicker
Elmar Dr.Phil.Nat. 6940 Weinheim De Bosies
Rainer Dipl.-Chem. Dr.Rer.Nat. 6800 Mannheim De Haage
Dieter Dr.Med. 6900 Heidelberg De Herrmann
Wolfgang Dr.Rer.Nat. 6805 Heddesheim De Kampe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Priority to DE3825667A priority Critical patent/DE3825667A1/de
Priority to DE3844655A priority patent/DE3844655A1/de
Priority to EP89113425A priority patent/EP0352652B1/de
Priority to DK198903633A priority patent/DK175199B1/da
Priority to AT89113425T priority patent/ATE117551T1/de
Priority to DE58908926T priority patent/DE58908926D1/de
Priority to PH38984A priority patent/PH26684A/en
Priority to AU38877/89A priority patent/AU619027B2/en
Priority to CA000606620A priority patent/CA1333771C/en
Priority to IL9113889A priority patent/IL91138A/en
Priority to PT91293A priority patent/PT91293B/pt
Priority to IE244889A priority patent/IE66680B1/en
Priority to HU893821A priority patent/HU206827B/hu
Priority to ZA895710A priority patent/ZA895710B/xx
Priority to JP1194417A priority patent/JP2848634B2/ja
Priority to KR1019890010705A priority patent/KR0135757B1/ko
Publication of DE3825667A1 publication Critical patent/DE3825667A1/de
Application granted granted Critical
Publication of DE3825667C2 publication Critical patent/DE3825667C2/de
Priority to US08/026,210 priority patent/US5369119A/en
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
DE3825667A 1988-07-28 1988-07-28 Verwendung von imexon als immunsuppressivum Granted DE3825667A1 (de)

Priority Applications (17)

Application Number Priority Date Filing Date Title
DE3825667A DE3825667A1 (de) 1988-07-28 1988-07-28 Verwendung von imexon als immunsuppressivum
DE3844655A DE3844655A1 (de) 1988-07-28 1988-07-28 Verwendung von imexon als immunsuppressivum
EP89113425A EP0352652B1 (de) 1988-07-28 1989-07-21 Verwendung von Imexon als Immunsuppressivum
DK198903633A DK175199B1 (da) 1988-07-28 1989-07-21 Anvendelse af imexon som immunsuppressivt middel
AT89113425T ATE117551T1 (de) 1988-07-28 1989-07-21 Verwendung von imexon als immunsuppressivum.
DE58908926T DE58908926D1 (de) 1988-07-28 1989-07-21 Verwendung von Imexon als Immunsuppressivum.
PH38984A PH26684A (en) 1988-07-28 1989-07-21 The use of imexone as an immune suppressive and pharmaceutical compositions containing them
AU38877/89A AU619027B2 (en) 1988-07-28 1989-07-24 Method for suppressing immune responses by administering imexon
CA000606620A CA1333771C (en) 1988-07-28 1989-07-25 Use of imexon as an immune suppressive and pharmaceutical compositions containing them
IL9113889A IL91138A (en) 1988-07-28 1989-07-27 Immunosuppressive preparations containing Imaxon
PT91293A PT91293B (pt) 1988-07-28 1989-07-27 Processo para a preparacao de composicoes farmaceuticas com actividade imunossupressiva, contendo 4-imino-1,3-diazabiciclo -(3.1.0)-hexano-2-ona
IE244889A IE66680B1 (en) 1988-07-28 1989-07-27 The use of imexon as an immune suppressive
HU893821A HU206827B (en) 1988-07-28 1989-07-27 Process for producing pharmaceutical compositions containing imexone as active component with specifical immunosuppressive activity
ZA895710A ZA895710B (en) 1988-07-28 1989-07-27 The use of imexon as immune suppressive and pharmaceutical compositions containing imexon
JP1194417A JP2848634B2 (ja) 1988-07-28 1989-07-28 免疫抑制作用を有する医薬
KR1019890010705A KR0135757B1 (ko) 1988-07-28 1989-07-28 이멕손을 포함하는 약학적 조성물
US08/026,210 US5369119A (en) 1988-07-28 1993-03-02 Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3825667A DE3825667A1 (de) 1988-07-28 1988-07-28 Verwendung von imexon als immunsuppressivum

Publications (2)

Publication Number Publication Date
DE3825667A1 DE3825667A1 (de) 1990-03-15
DE3825667C2 true DE3825667C2 (OSRAM) 1991-06-27

Family

ID=6359767

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3825667A Granted DE3825667A1 (de) 1988-07-28 1988-07-28 Verwendung von imexon als immunsuppressivum
DE58908926T Expired - Fee Related DE58908926D1 (de) 1988-07-28 1989-07-21 Verwendung von Imexon als Immunsuppressivum.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE58908926T Expired - Fee Related DE58908926D1 (de) 1988-07-28 1989-07-21 Verwendung von Imexon als Immunsuppressivum.

Country Status (14)

Country Link
EP (1) EP0352652B1 (OSRAM)
JP (1) JP2848634B2 (OSRAM)
KR (1) KR0135757B1 (OSRAM)
AT (1) ATE117551T1 (OSRAM)
AU (1) AU619027B2 (OSRAM)
CA (1) CA1333771C (OSRAM)
DE (2) DE3825667A1 (OSRAM)
DK (1) DK175199B1 (OSRAM)
HU (1) HU206827B (OSRAM)
IE (1) IE66680B1 (OSRAM)
IL (1) IL91138A (OSRAM)
PH (1) PH26684A (OSRAM)
PT (1) PT91293B (OSRAM)
ZA (1) ZA895710B (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005055952A2 (en) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528460A1 (de) * 1975-06-26 1977-01-13 Boehringer Mannheim Gmbh Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans
DE2530398A1 (de) * 1975-07-08 1977-01-27 Boehringer Mannheim Gmbh Organische verbindung
DE2736296A1 (de) * 1977-08-12 1979-02-22 Boehringer Mannheim Gmbh Verwendung von 2-cyan-aziridin und seinen derivaten zur immunstimulierung

Also Published As

Publication number Publication date
DK363389D0 (da) 1989-07-21
EP0352652B1 (de) 1995-01-25
DE58908926D1 (de) 1995-03-09
CA1333771C (en) 1995-01-03
PH26684A (en) 1992-09-15
DK363389A (da) 1990-01-29
IE66680B1 (en) 1996-01-24
DK175199B1 (da) 2004-07-05
JP2848634B2 (ja) 1999-01-20
EP0352652A2 (de) 1990-01-31
EP0352652A3 (de) 1991-09-04
AU619027B2 (en) 1992-01-16
HU206827B (en) 1993-01-28
IE892448L (en) 1990-01-28
PT91293B (pt) 1995-03-01
JPH0288521A (ja) 1990-03-28
IL91138A0 (en) 1990-03-19
AU3887789A (en) 1990-02-01
ZA895710B (en) 1990-04-25
IL91138A (en) 1994-10-21
ATE117551T1 (de) 1995-02-15
KR0135757B1 (ko) 1998-04-23
HUT52378A (en) 1990-07-28
PT91293A (pt) 1990-02-08
KR900001369A (ko) 1990-02-27
DE3825667A1 (de) 1990-03-15

Similar Documents

Publication Publication Date Title
EP0559238B1 (de) Cyancrotonsäureamidverbindung als Arzneimittel mit immunmodulierenden Eigenschaften
DE60202278T2 (de) Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten
DE3318649A1 (de) Zweiphasenformulierung
DE69833333T2 (de) Pharmazeutische zusammensetzung enthaltend geweihextrakte von cervus nippon mit wachstumsstimulierender aktivität auf hematopoietische stammzellen und megakaryozyten
CH641357A5 (de) Pharmazeutisches praeparat mit polymerbeschichtungen, enthaltend herzglykoside.
EP0346501B1 (de) Arzneimittelzubereitung zur behandlung des immunmangels
DE3611194A1 (de) Cancerostatisches mittel
DE4321444A1 (de) Pharmazeutische Zubereitung
DE69323759T2 (de) Verwendung von toremifene für die behandlung von sle
EP0040325A1 (de) Verwendung von Adenosinderivaten zur Herstellung eines Psychopharmakons
EP0607776A2 (de) Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
DE2520978C3 (de) Dosierungseinheit einer festen, oral zu verabreichenden Arzneiform von wasserlöslichen Xanthin-Derivaten
DE69226487T2 (de) Verwendung von Furanonderivaten zur Vorbeugung oder Behandlung von Autoimmunkrankheiten
EP0607777A2 (de) Verwendung von Leflunomid zur Herstellung von Interleukin 8
DE69115528T2 (de) Neue pharmazeutische Verwendungen von Forskolin-Derivaten
DE3825667C2 (OSRAM)
DE69003670T2 (de) Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs.
DE3844839C2 (de) Verwendung von Imexon als Immunsuppressivum
DE69626548T2 (de) Macrocyclische verbindungen die aus kohlensuboxi-gruppen besteht
DE3212909C2 (OSRAM)
DE3736691C2 (OSRAM)
DE3844655A1 (de) Verwendung von imexon als immunsuppressivum
DE19514048A1 (de) Trapidil zur Verwendung in der Therapie von immunmodulatorisch beeinflußbaren Krankheitsbildern
EP0205077A2 (de) Suramin-Natrium zur Verwendung als Immunstimulans
US5369119A (en) Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon

Legal Events

Date Code Title Description
AH Division in

Ref country code: DE

Ref document number: 3844655

Format of ref document f/p: P

OP8 Request for examination as to paragraph 44 patent law
AH Division in

Ref country code: DE

Ref document number: 3844655

Format of ref document f/p: P

AH Division in

Ref country code: DE

Ref document number: 3844655

Format of ref document f/p: P

D2 Grant after examination
8364 No opposition during term of opposition
AH Division in

Ref country code: DE

Ref document number: 3844655

Format of ref document f/p: P

8339 Ceased/non-payment of the annual fee